Last Updated: 16 Sep 2024
Executive Summary
ENDRA Life Sciences Inc. (NDRA) is a clinical diagnostic ultrasound technology developer. Despite its promising technology, the company faces challenges, including negative earnings and revenue, low market capitalization, and a lack of profitability. The stock price has declined significantly in recent years, reaching $0.23. While the company has a strong analyst rating and a low price-to-book ratio, it also has a high beta and significant debt.
Company Overview
ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan. The company develops and markets ultrasound systems for various clinical applications, including cardiology, radiology, and obstetrics/gynecology. ENDRA's technology aims to improve image quality, reduce examination time, and enhance diagnostic accuracy.
Fundamental Analysis
Financials: ENDRA has reported negative earnings and revenue in recent quarters. The company's EBITDA for the latest quarter was -$9,520,298, and its diluted EPS was -$32. The company has a low market capitalization of $3,974,600 and a negative return on assets and equity.
Valuation: ENDRA's stock price has declined significantly in recent years. The current price-to-book ratio is 0.442, indicating that the stock is undervalued compared to its book value. However, the company has a high beta of 0.809, indicating high volatility.
Technical Analysis
Trend: The stock price has been in a downtrend since 2021. It has recently broken below its 50-day and 200-day moving averages, indicating further downside potential.
Support and Resistance: The stock has support at $0.21 and resistance at $0.25. A break below support could lead to further declines, while a break above resistance could indicate a potential reversal.
Short Term Outlook
In the short term, ENDRA's stock price is likely to remain under pressure due to its weak fundamentals and negative technical indicators. The stock could continue to decline towards its support level at $0.21.
Long Term Outlook
The long-term outlook for ENDRA is uncertain. The company needs to improve its financial performance and address its debt concerns. If ENDRA can successfully execute its business plan and achieve profitability, the stock could have upside potential. However, the company faces significant competition in the medical device industry, and it may take time to gain market share.
Analyst Recommendations
Analysts have a mixed view on ENDRA. One analyst has a "Buy" rating, while the others have "Hold" ratings. The average analyst target price is $10, which implies significant upside potential from the current price. However, investors should note that analyst recommendations can change over time and should not be relied upon as the sole basis for investment decisions.
